Dossier assessment

Talazoparib (breast cancer) - Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A20-48
Last updated

Report documents

  1. Extract of dossier assessment

    Talazoparib (breast cancer) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 758 kB, EN, not accessible
  2. Dossier assessment

    Talazoparib (breast cancer) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 2 MB, DE, not accessible

Dossier assessment

Indication:

Adults with BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer

Result of dossier assessment:

Hint of considerable added benefit

Press releases

Talazoparib in breast cancer: hint of considerable added benefit

Advantages in health-related quality of life, symptoms and side effects outweigh disadvantages

Additional information

Federal Joint Committee (G-BA)

20.11.2020 A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
A20-48
Commission
Commission awarded on 29.05.2020 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer

Connected Projects

  1. Addendum

    Talazoparib (breast cancer) - Addendum to Commission A20-48

    Project no.
    A20-89
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Talazoparib (prostate cancer) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A24-22
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form